Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
NCT03969004Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2019
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 16
01
Overview
A Phase 3 trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Regeneron Pharmaceuticals. Started Jun 2019; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT03969004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969004.